SCHEMBL2804134

SCHEMBL2804134

Brc1n[nH]c2ncnc(NC3CCc4c(cnc5[nH]ncc45)C3)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.44
PAK1 Q13153 6/20 0.38
GRIN2B Q13224 9/20 0.36
KCNH2 Q12809 3/20 0.36
CYP2D6 P10635 1/20 0.36
MAPK1 P28482 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
PDPK1 O15530 1/20 0.35
RET P07949 1/20 0.35
PI4KA P42356 1/20 0.35
XDH P47989 1/20 0.35
LRRK2 Q5S007 1/20 0.35
PI4K2B Q8TCG2 1/20 0.35
PI4K2A Q9BTU6 1/20 0.35
PI4KB Q9UBF8 1/20 0.35
CCNT1 O60563 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
CCNA1 P78396 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805753 0.79 HPGDS (0.46) HPGDSPAK1GRIN2BKCNH2CYP2D6
SCHEMBL12316008 0.75 HPGDS (0.43) HPGDSPAK1GRIN2BKCNH2CYP2D6
SCHEMBL12316006 0.72 HPGDS (0.36) HPGDSRETPI4KAXDHLRRK2
SCHEMBL12315722 0.70 MALT1 (0.35) HPGDSPAK1GRIN2BMKNK1CDK2
SCHEMBL2487631 0.70 HPGDS (0.36) HPGDSGRIN2BKCNH2CYP2D6PDPK1
SCHEMBL13273855 0.70 DRD2 (0.43) HPGDS
SCHEMBL12316007 0.70 HPGDS (0.36) HPGDSXDHCDK2
SCHEMBL2805162 0.70 HPGDS (0.34) HPGDSRETXDHLRRK2
SCHEMBL2803956 0.69 MAPK8 (0.36) HPGDSXDH
SCHEMBL12338145 0.69 MTNR1A (0.47) HPGDSPAK1MAPK1CDK2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 HPGDS 167/4885PAK1 717/4885GRIN2B 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.